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Abstract. Cancer is a major health problem in both developed and developing countries. In women, cancer incidence 
rates increased every year. Developments in treatment modalities and the ability to detect tumours in the early stages 
increased their survival rate but also raise fertility problems. Those problems are the fertility preservation for patient who 
have to endure gonadotoxic chemotherapy and or radiation even though they still need their fertility functions. Ovarian 
cryopreservation and autotransplantation were initially designed to protect and restore reproductive function in patients 
receiving sterilizing chemotherapy and/or radiotherapy. Other indications including patients undergoing haematopietic 
stem cell transplantation, autoimmune diseases and those undergoing oophorectomy for non-cancer conditions. Options 
in cryopreserved ovarian tissues include autotransplantation and xenotransplantation. An orthotopic site or a heterotopic 
site can be considered for autotransplantation. Xenotransplantation of human ovarian tissue into immunodeficient 
animals can prevent immunological rejection.  The theoretical advantage of orthotopic grafts is the restoration of normal 
reproductive function and natural conception after transplantation but application for cancer patients is problematic 
because of the potential risk of transmission of microscopic metastatic disease. With Xenotransplantantion, the possibility 
of cancer transmission and relapse can be eliminated because cancer cells cannot penetrate the zona pellucida, and some 
technical difficulties of in vitro growth and maturation of primordial follicles can be bypassed. But it is still unknown 
whether conditions for the growth and maturation of human oocytes in an animal host are comparable to those in situ 
and whether animal pathogens can be transmitted to human tissue with it. Ovarian tissue cryopreservation is the fertility 
preservation option for prepubertal girls and for women who face thehigh likelihood of diminished ovarian reserve 
requiring immediate treatment. Its procedure are still within improvement and also in the study of understanding its 
mechanism. In the future, studies and large clinical trials are still needed to develop better cryoprotectants and 
cryopreservation protocols and also standardization - optimization transplantation techniques 
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Introduction 
Cancer is a major health problem in both developed and developing countries.1 In women, 
cancer incidence rates increased every year. Developments in treatment modalities and the 
ability to detect tumours in the early stages increased survival rate but also raise fertility 
problems.Those problems are the fertility preservation for patient who have to endure 
gonadotoxic chemotherapy and or radiation even though they still need their fertility functions.. 
Many treatments that are administered for childhood and adolescent cancers carry a substantial 
risk for infertility.2 This risk varies according to the presenting pathology and requires preventive 
treatment. It was estimated 1 in 1,000 adults was a survivor of childhood cancer. Over the last 
decade, the field of ovarian transplantation and cryopreservation has significantly progressed, 
becoming applicable in humans. Cryopreservation of embryos is a standard technique for fertility 
preservation when there is adequate time for ovarian stimulation1 But this technique requires at 
least 2 weeks from the beginning of the menstrual cycle, which may not be available to all 
patients with cancer. Furthermore, embryo cryopreservation requires a partner and ovarian 
stimulation, both of which are not possible in prepubertal girls.3 Ovarian cryopreservation and 
autotransplantation are the other method and were initially designed to protect and restore 
reproductive function in patients receiving sterilizing chemotherapy and/or radiotherapy. Other 
indications including patients undergoing haematopietic stem cell transplantation, autoimmune 
diseases and those undergoing oophorectomy for non-cancer conditions 
Indications 
Premature ovarian failure (POF) is a wellknown consequence of exposing female gonads 
to chemotherapeutic drugs. The indications now include not only neoplastic diseases but also 
non-neoplastic conditions requiring chemotherapy, radiotherapy or haematopoietic stem cell 
transplantation. Oophorectomy for benign ovarian tumours and for BRCA germline mutations can 
also be indications.2 It was used in treating Hodgkin’s disease, breast cancer or during treatment 
for autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.2 
Histological sections of the ovary after exposure to cytotoxic drugs show a spectrum of changes 
Proceedings of The 2nd Annual International Conference Syiah Kuala University 2012  
& The 8th IMT-GT Uninet Biosciences Conference 
Banda Aceh, 22-24 November 2012 
 
357 
Volume 2 Number 1, 2012 
 
ranging from decreased numbers of follicles to absent follicles to fibrosis. 4 The population of 
women who may potentially require gonadal protection against alkylating agents is quite large. 
Twenty-five percent of breast cancer is diagnosed in women who are under the age of 50. With 
the typical regimen of CMF (cyclophosphamide, methotrexate, fluorouracil), two-thirds of women 
will become amenorrhea. With the AC (doxorubicin, cyclophosphamide) protocol, 34% will be 
amenorrheic at 3 years. This percentage increases if taxanes are also used with this regimen.  
Some Indication for ovarian tissue cryoperservation1 
Cancer in children 
Breast cancer 
Cervical cancer 
Autoimmune and hematological disease 
Surgery for benign ovarian disease 
Patients receiveng pelvic radiation 
Prohylactic oophorectomy 
Ovarian cryopreservation 
Cryopreservation of ovarian cortex combined with orthotopic transplantation into an 
irradiated ovary restored fertility in rodents 50 years ago 5. The ability to preserve oocytes and 
ovarian tissues in a healthy state for a variable duration gives the patient who will undergo 
cancer treatment another option to preserve her fertility.2, 6-7 A major advantage of ovarian 
cryopreservation is that this technique does not delay cancer treatment, unlike cryopreservation 
of embryos or oocytes.8 Cryopreservation of oocytes and gonadal tissues (i.e., ovarian and 
testicular tissue) is a rapidly evolving area in reproductive medicine.9 It relies on the principle 
that the primordial follicles withstand the cryo-toxicity better than the growing follicle. A 
relatively inactive metabolism, lack of zona pellucida, and metaphase spindle grant this privilege 
to primordial. In addition, smaller cell size allows faster penetration of cryoprotectants in the 
oocyte.9-10 11The main factor that may influence the outcome in oocyte cryopreservation is its 
structural complexity. Oocyte subcellular organelles are far more complex and perhaps more 
sensitive to thermal injury than preimplantation embryos.2 
Xenografting studies of human ovarian tissue 
Cortical fragments of human ovarian tissue can be xenotransplanted into T- and B-cell-
deficient SCID mice. It was demonstrated that cryopreservation and xenotransplantation did not 
appear to greatly affect the human primordial/primary follicle ultrastructure. Interestingly, in 
frozen– thawed xenografts, secondary human ovarian follicles presented a well-preserved 
ultrastructure, but asynchrony between oocytes and granulosa cell development was detected.12 
GnRH agonist treatment did not prevent primordial follicle depletion after the xenografting of 
ovarian tissue in SCID mice with or without gonadotropin stimulation.13 Furthermore, GnRHa 
caused an additional loss of follicles if administered during the critical neo-vascularisation period 
after the transplantation until now its use as a means to use banked ovarian tissue is in 
question.1, 3, 10  Concerns regarding cross-species retroviral infections should also be addressed. 
With this technique, the possibility of cancer transmission and relapse can be eliminated because 
cancer cells cannot penetrate the zona pellucida, and some technical difficulties of in vitro growth 
and maturation of primordial follicles can be bypassed. Additionally, this technique can be applied 
to patients at high risk for hyperstimulation syndrome (e.g., polycystic ovary syndrome) or to 
patients for whom hormonal replacement therapy is contraindicated such as those with breast 
cancer.8 It is unknown whether conditions for the growth and maturation of human oocytes in an 
animal host are comparable to those in situ. It is also of concern that animal pathogens can be 
transmitted to human tissue with xenografting. 8, 14-15 
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Fig 1. Options for development of immature oocytes in cryopreserved ovarian tissues 4 
Human Ovarian cortex transplantation 
There are two main approaches for autotransplantation of human ovarian tissue. In the 
heterotopic transplantation, cortical fragments can be grafted subcutaneously at various sites; 
such as forearm and abdominal wall. 16In orthotopic transplantation, ovarian cortical fragments 
are transplanted into its original location, on the remaining ovary or near the infundibulopelvic 
ligaments or ovarian fossa.1 
Orthotopic transplantation 
The advantage of orthotopic transplantation is that a natural pregnancy can occur; 
however, the procedure requires abdominal surgery and general anaesthesia. However, 
orthotopic location is not preferred when the risk of ovarian metastasis is high because tissue 
monitoring may be more difficult.17 
Heterotopic transplantation 
In this technique, general anaesthesia or abdominal surgery is not required, follicle 
monitoring and, when necessary, removal of transplanted tissue is easier in a subcutaneous site. 
Various body sites can be used to graft ovarian pieces, subcutaneous space above the 
brachioradialis facia of the forearm or under rectus sheet in lower abdomen. Heterotopic 
transplantation may be indicated if the pelvis is not suitable for transplantation due to previous 
radiation or severe scar formation. Furthermore, easy tissue monitoring is an advantage of 
heterotopic transplantation.There are still numerous challenges to perfecting the heterotopic 
ovarian transplants as the oocyte maturation process appears to occur differently than in the 
orthotopic environment.It can also be done through laparoscopic process. 18-21 
Freezing/ thawing of ovarian cortex may be indicated for adult women who cannot delay 
the start of chemotherapy, making controlled ovarian stimulation for oocyte or embryo freezing 
unrealistic. In addition, it is the only option available for prepubertal girls to save their fertility. 
Two techniques have been reported. The first option ito extract around 50% of one ovary by 
removing a block of cortical tissue or by removing 5–10 ovarian cortex biopsies with an average 
volume of around 5 mm3 per biopsy.22 
t is now well established that adequate penetration of cryoprotectant through the stroma 
and granulosa cells to the oocytes is required for obtaining satisfactory results. rates. The choice 
of cryoprotectant with maximum permeation capacity but minimum toxicity and ice crystal 
formation potential is specific to each cell and tissue type. In the ovary, this choice requires the 
adequate compromise among the stroma, the follicular cells, and the oocytes.5 Human studies 
comparing slow-freezing protocols with vitrification of ovarian tissue have produced conflicting 
results, which may be explained by differences in the protocols and the medium used. However, 
transmission electron microscopy data suggest that vitrification could be more effective than 
slow-programmed freezing when cryopreserving ovarian tissue 
Whole ovary cryopreservation 
Cryopreservation of whole human ovary is a challenging issue. First, human ovary is 
larger and more complex than the ovaries of the animals; and second, it may be challenging to 
devise a cryopreservation protocol that will optimally preserve both the ovarian follicles and 
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vasculature structures. Several authors demonstrated that cryopreservation of intact human 
ovary with its vascular pedicle is not associated with any signs of apoptosis or ultrastructural 
alterations in any cell types. However there has been no case of successful ovarian 
transplantation with whole-frozen ovarian tissue and no study reported on the functionality of 
ovaries frozen intact.23 
 
The Dangers 
There are still risks of re-implanting an occult tumour with frozen– thawed ovarian pieces; 
When there is a high risk of ovarian metastasis, ovarian transplantation for the purposes of 
future autotransplantation should not be performed. Patients with high-risk cancers either should 
not be given the option of ovarian autotransplantation or ovarian tissue harvest should be 
performed after the first round of chemotherapy in order to clear any neoplastic cells residing in 
the ovary. However, it should be stressed that the ovarian reserve and effectiveness of assisted 
reproductive technologies diminish with each round of chemotherapy administered.1, 24 In all 
cancer patients, to further minimize the risk of cryopreserving cancer cells with ovarian tissue, 
multiple biopsies should be taken from the ovary and a thorough histological analysis should be 
performed. Additionally, when there is a marker, molecular biology techniques as well as 
immunostaining can be used to detect occult metastasis 25 
Regardless of the application, the practitioner should have a  thorough discussion with the 
patient regarding all the available options and make it clear that most fertility preservation 
options are currently experimental.1 In vitro maturation of primordial follicles and ovarian tissue 
xenotransplantation may 1 day become common applications in conjunction with the 
cryopreservation of ovarian tissue. To avoid possible reimplantation of malignant cells, two 
approaches have been suggested, such as grafting of isolated follicles in an artificial ovary and in 
vitro maturation of primordial follicles In this setting, a whole ovary cryopreservation has an 
advantage over cortical strips.5 
 
Conclusions 
Ovarian tissue cryopreservation is the fertility preservation option for prepubertal girls 
and for women who face thehigh likelihood of diminished ovarian reserve requiring immediate 
treatment. Its procedure are still within improvement and also in the study of understanding its 
mechanism. In the future , studies and large clinical trials are still needed to develop better 
cryoprotectants and cryopreservation protocols and also standardization - optimization 
transplantation techniques  
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